- Infante-Menéndez, Jorge
- López-Pastor, Andrea R.
- González-Illanes, Tamara
- González-López, Paula
- Huertas-Lárez, Raquel
- Rey, Esther
- González-Rodríguez, Águeda
- García-Monzón, Carmelo
- Patil, Nikita P.
- Vega de Céniga, Melina
- Baker, Aaron B.
- Gómez-Hernández, Almudena
- Escribano, Óscar
[Background and Aims]: The molecular mechanisms driving non-alcoholic fatty liver disease (NAFLD) are poorly understood; however, microRNAs might play a key role in these processes. We hypothesize that let-7d- 5p could contribute to the pathophysiol-ogy of NAFLD and serve as a potential diagnostic biomarker., [Methods]: We evaluated let-7d- 5p levels and its targets in liver biopsies from a cross- sectional study including patients with NAFLD and healthy donors, and from a mouse model of NAFLD. Moreover, the induction of let-7d- 5p expression by fatty acids was evaluated in vitro. Further, we overexpressed let-7d- 5p in vitro to corroborate the results observed in vivo. Circulating let-7d- 5p and its potential as a NAFLD biomarker was determined in isolated extracellular vesicles from human plasma by RT-qPCR., [Results]: Our results demonstrate that hepatic let-7d-5p was significantly up-regulated in patients with steatosis, and this increase correlated with obesity and a decreased expression of AKT serine/threonine kinase (AKT), insulin-like growth factor 1 (IGF1), IGF-I receptor (IGF1R) and insulin receptor (INSR). These alterations were corroborated in a NAFLD mouse model. In vitro, fatty acids increased let-7d-5p expression, and its overexpression decreased AKT, IGF-IR and IR protein expression. Furthermore, let-7d-5p hindered AKT phosphorylation in vitro after insulin stimulation. Finally, circulating let-7d-5p significantly decreased in steatosis patients and receiver operating characteristic (ROC) analyses confirmed its utility as a diagnostic biomarker., [Conclusions]: Our results highlight the emerging role of let-7d-5p as a potential therapeutic target for NAFLD since its overexpression impairs hepatic insulin signalling, and also, as a novel non-invasive biomarker for NAFLD diagnosis., This work was supported by grants RTI-2018-095098-B100 and PID2021-123076OB-I00 from the Ministerio de Ciencia, Innovación y Universidades, AENC1/22-29754 from UCM and PR75/18-21572 from Santander-UCM given to AG-H and OE; grants PI20/00837 and PI19/00123 from Instituto de Salud Carlos III (ISCIII, Spain) and Fondo Europeo para el Desarrollo Regional (FEDER) given to CG-M and AG-R respectively. The authors gratefully acknowledge funding though the American Heart Association (17IRG33410888), the DOD CDMRP (W81XWH-16-1-0580; W81XWH-16-1-0582) and the National Institutes of Health (1R21EB023551-01; 1R21EB024147-01A1; 1R01HL141761-01) to ABB. JI-M and PG-L were funded by the Consejería de Ciencia, Universidades e Innovación from Comunidad de Madrid and the European Social Fund., Peer reviewed